Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M.M. Streng; Marin Bont; Eveline M. Delemarre; Rob S. Binnendijk; Gaby Smit; Gerco den Hartog; Antonia M.W. Coppus; Esther de Vries; Michel E. Weijerman; Regina Lamberts; Gert de Graaf; Fiona R. van der Klis; Gestur Vidarsson; Neele Rave; Louis J. Bont; Joanne G. Wildenbeest

doi:10.1093/infdis/jiac235

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M.M. Streng, Marin Bont, Eveline M. Delemarre, Rob S. Binnendijk, Gaby Smit, Gerco den Hartog, Antonia M.W. Coppus, Esther de Vries, Michel E. Weijerman, Regina Lamberts, Gert de Graaf, Fiona R. van der Klis, Gestur Vidarsson, Neele Rave, Louis J. Bont, Joanne G. Wildenbeest

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

Samenvatting

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.

Originele taal-2	Engels
Pagina's (van-tot)	673-677
Aantal pagina's	5
Tijdschrift	The Journal of infectious diseases
Volume	226
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1093/infdis/jiac235
Status	Gepubliceerd - 4 sep. 2022
Extern gepubliceerd	Ja

Toegang tot document

10.1093/infdis/jiac235

Citeer dit

Streng, B. M. M., Bont, M., Delemarre, E. M., Binnendijk, R. S., Smit, G., den Hartog, G., Coppus, A. M. W., de Vries, E., Weijerman, M. E., Lamberts, R., de Graaf, G., van der Klis, F. R., Vidarsson, G., Rave, N., Bont, L. J., & Wildenbeest, J. G. (2022). Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome. The Journal of infectious diseases, 226(4), 673-677. https://doi.org/10.1093/infdis/jiac235

@article{d4fac0d3971d4b8c87c627a2d9cce1c7,

title = "Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome",

abstract = "The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.",

keywords = "antibody response, COVID-19 vaccination, Down syndrome, SARS-CoV-2",

author = "Streng, {Bianca M.M.} and Marin Bont and Delemarre, {Eveline M.} and Binnendijk, {Rob S.} and Gaby Smit and {den Hartog}, Gerco and Coppus, {Antonia M.W.} and {de Vries}, Esther and Weijerman, {Michel E.} and Regina Lamberts and {de Graaf}, Gert and {van der Klis}, {Fiona R.} and Gestur Vidarsson and Neele Rave and Bont, {Louis J.} and Wildenbeest, {Joanne G.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2022",

month = sep,

day = "4",

doi = "10.1093/infdis/jiac235",

language = "English",

volume = "226",

pages = "673--677",

journal = "The Journal of infectious diseases",

issn = "1537-6613",

publisher = "Oxford University Press",

number = "4",

}

Streng, BMM, Bont, M, Delemarre, EM, Binnendijk, RS, Smit, G, den Hartog, G, Coppus, AMW, de Vries, E, Weijerman, ME, Lamberts, R, de Graaf, G, van der Klis, FR, Vidarsson, G, Rave, N, Bont, LJ & Wildenbeest, JG 2022, 'Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome', The Journal of infectious diseases, vol. 226, nr. 4, blz. 673-677. https://doi.org/10.1093/infdis/jiac235

TY - JOUR

T1 - Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

AU - Streng, Bianca M.M.

AU - Bont, Marin

AU - Delemarre, Eveline M.

AU - Binnendijk, Rob S.

AU - Smit, Gaby

AU - den Hartog, Gerco

AU - Coppus, Antonia M.W.

AU - de Vries, Esther

AU - Weijerman, Michel E.

AU - Lamberts, Regina

AU - de Graaf, Gert

AU - van der Klis, Fiona R.

AU - Vidarsson, Gestur

AU - Rave, Neele

AU - Bont, Louis J.

AU - Wildenbeest, Joanne G.

PY - 2022/9/4

Y1 - 2022/9/4

N2 - The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.

AB - The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.

KW - antibody response

KW - COVID-19 vaccination

KW - Down syndrome

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85137153699&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac235

DO - 10.1093/infdis/jiac235

M3 - Article

C2 - 35748853

AN - SCOPUS:85137153699

VL - 226

SP - 673

EP - 677

JO - The Journal of infectious diseases

JF - The Journal of infectious diseases

SN - 1537-6613

IS - 4

ER -

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit